Staphylococcal Skin Infections Clinical Trial
Official title:
An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients =3 Months to 17<18 Years of Age, Undergoing Treatment With Systemic Antibiotics
This study will assess the pharmacokinetics (how drugs are absorbed, distributed in the body and removed over time) and safety of a single dose of ceftobiprole in pediatric patients undergoing treatment with systemic antibiotics and may be used to guide dosing recommendations for ceftobiprole in children.
This purpose of this study will be to assess the pharmacokinetics (how drugs are absorbed, distributed in the body and removed over time) and safety of a single dose of ceftobiprole in pediatric patients undergoing treatment with systemic antibiotics and may be used to guide dosing recommendations for ceftobiprole in children. This study is an open-label (all patients will know the identity of the drug) single-dose, pharmacokinetic study in infants and children =3 months to <18 years of age who are medically stable as judged by the clinical investigator and require therapy with antibiotics. Patients will be given a 2-hour i.v. infusion (given directly into the vein) of 7, 10, or 15 mg/kg ceftobiprole. The study population will be grouped according to the following 4 age groups: =12 to <18 years of age; =6 to <12 years of age; =2 to <6 years of age; and =3 months to <2 years of age. Every attempt will be made to include patients of both sexes in each age group. Safety evaluations will include clinical laboratory tests (hematology, serum chemistry, and urinalysis), pregnancy testing, vital signs, physical examination, monitoring of adverse events, and recording of concomitant medications. Patients will be given a single 2-hour i.v. (given directly into the vein) infusion of ceftobiprole. The total duration of the study is approximately 18 days, including screening and posttreatment. ;
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01419184 -
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
|
Phase 4 | |
Completed |
NCT00210899 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Recruiting |
NCT02566928 -
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence
|
Phase 4 | |
Completed |
NCT00228982 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT01105767 -
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
|
N/A | |
Completed |
NCT01030731 -
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
|
Phase 1 | |
Completed |
NCT00475930 -
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates
|
N/A | |
Completed |
NCT02814916 -
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
|
Phase 3 | |
Completed |
NCT00513799 -
The Natural History of Community-Associated MRSA Infections and Decolonization Strategies
|
N/A | |
Completed |
NCT00719810 -
Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections
|
Phase 2 | |
Completed |
NCT00737269 -
A Complicated Skin and Soft-tissue Infection Patient Registry
|
Phase 4 | |
Completed |
NCT01026740 -
Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT00492271 -
First Time in Man Trial for Friulimicin B
|
Phase 1 | |
Completed |
NCT00731783 -
Staphylococcus Aureus Decolonization Study
|
N/A | |
Completed |
NCT01018641 -
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
|
Phase 1 | |
Terminated |
NCT00463801 -
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
|
Phase 4 | |
Completed |
NCT02582203 -
Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
|
Phase 4 | |
Completed |
NCT00646958 -
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
|
Phase 2 | |
Completed |
NCT00514527 -
A Study for Patients With Complicated Skin and Skin Structure Infections
|
Phase 2 | |
Completed |
NCT01026558 -
A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
|
Phase 1 |